Treatment of Metastatic Cancer in Terminally Diagnosed Patients
Sponsor: Matrix Biomed, Inc.
ClinicalTrials ID:NCT05491928
Tempol, an adjunct to chemotherapy, aims to enhance treatment response and reduce chemoresistance in terminally diagnosed metastatic cancer patients. It protects non-cancerous cells, allowing higher chemotherapy doses by mitigating side effects. Eligibility is limited to those with metastatic terminal diagnoses. Tempol targets HIF-1/VEGF in cancer cells and upregulates GSH/NrF2 in healthy cells.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The objective is to provide terminally diagnosed patients with a last line of treatment while improving overall quality of life. Tempol can be added to any chemotherapy regimen to potentially reduce side effects and overcome chemoresistance.
Description
The objective is to provide terminally diagnosed patients assigned to palliative care and palliative chemotherapy a last line treatment with Tempol. In vivo studies have shown Tempol to work synergistically with a number of chemotherapy agents increasing treatment response and reducing chemoresistance. Additionally, Tempol has been shown to provide protection to non-cancerous cells allowing for increased chemotherapy dosing by reducing side effects. Tempol inhibits HIF-1/VEGF among others in cancerous cells while upregulating GSH/NrF2 among others in non-cancerous cells.
Eligibility Criteria
Inclusion Criteria
- metastatic terminally diagnosed cancer
Exclusion Criteria
Get This Program In Your Inbox
You can sign up and apply your patients for this program.